rapa-201 autologous t cells
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2020 (NCT04176380)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Melanoma · Phase 2
- Multiple Myeloma · Phase 2
- Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05144698 | Phase 2 | Aug 1, 2021 | Rapa Therapeutics LLC |
| NCT04176380 | Phase 2 | Mar 1, 2020 | Medical College of Wisconsin, Rapa Therapeutics LLC |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Rapa Therapeutics LLC | For profit | 2 | 2 | 1 | 2020 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1